| Subject: | FDA Alert - FDA Notifies of Revisions to Prescribing Information for Trasylol (aprotinin injection) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 19 Dec 2006 - 12:00 am |
| The FDA and Bayer Pharmaceuticals have notified healthcare professionals of revisions to the prescribing information for Trasylol. The new labeling has a more focused indication for use, a new Warning that Trasylol administration increases the risk of renal dysfunction and may increase the need for dialysis in the perioperative period, stronger warnings about anaphylactic reactions including a new Contraindication for previous aprotinin exposure.
In addition, due to the higher risk for... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
